Proteasome inhibition increases DNA and RNA oxidation in astrocyte and neuron cultures.
Increased levels of nucleic acid oxidation have been described as part of normal brain aging and have been demonstrated to occur in multiple neurological disorders. The basis for increased nucleic acid oxidation in each of these conditions is presently unknown. Proteasome inhibition occurs in a host of neurodegenerative conditions and likely contributes to increased levels of oxidative damage and neurotoxicity. In the present study we demonstrate for the first time the ability of proteasome inhibition to increase the level of nucleic acid oxidation in primary neuron and astrocyte cultures. Administration of proteasome inhibitors (MG262, MG115) at concentrations that do not induce neuron death in the first 24 h of treatment, dramatically increase the levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG) and 8-hydroxyguanosine (8OHG) immunoreactivity in both cell types. Neurons underwent larger increases in nucleic acid oxidation compared to astrocyte cultures. While both DNA and RNA oxidation were observed following proteasome inhibition, RNA appeared to undergo a greater degree of oxidation than DNA. Both 18S and 28S ribosomal RNA were dramatically decreased following proteasome inhibition. Interestingly, an accumulation of unprocessed and/or cross-linked RNA species was observed following proteasome inhibition. Taken together, these data indicate the ability of proteasome inhibition to increase the levels of nucleic acid oxidation in both neurons and astrocytes, and suggest that proteasome inhibition may have deleterious effects on transcription and translation in both neurons and glia.
Ding
Qunxing
Q
Department of Anatomy and Neurobiology, University of Kentucky, Lexington, Kentucky, USA.
Dimayuga
Edgardo
E
Markesbery
William R
WR
Keller
Jeffrey N
JN
D000818:Animals; D001253:Astrocytes / Q000187:drug effects* / Q000378:metabolism; D015153:Blotting, Western / Q000379:methods; D001897:Boronic Acids / Q000494:pharmacology; D001921:Brain / Q000166:cytology; D002478:Cells, Cultured; D004247:DNA / Q000378:metabolism*; D003839:Deoxyadenosines / Q000378:metabolism; D004622:Embryo, Mammalian; D006151:Guanosine / Q000031:analogs & derivatives* / Q000378:metabolism; D007150:Immunohistochemistry / Q000379:methods; D007976:Leupeptins / Q000494:pharmacology; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D010084:Oxidation-Reduction / Q000187:drug effects; D011480:Protease Inhibitors / Q000494:pharmacology*; D012313:RNA / Q000378:metabolism*; D012336:RNA, Ribosomal, 16S / Q000378:metabolism; D012339:RNA, Ribosomal, 28S / Q000378:metabolism; D051381:Rats; D013997:Time Factors
C436623:8-hydroxy-2'-deoxyadenosine; D001897:Boronic Acids; D003839:Deoxyadenosines; D007976:Leupeptins; C423917:MG 262; D011480:Protease Inhibitors; D012336:RNA, Ribosomal, 16S; D012339:RNA, Ribosomal, 28S; C089486:carbobenzoxy-leucyl-leucyl-norvalinal; D006151:Guanosine; C046215:8-hydroxyguanosine; D012313:RNA; D004247:DNA